Given that the bispecific treatment results in more favorable antitumor impacts contrasted to either SIRPα-CD47 axis or PD-1-PD-L1 axis blockade alone in mice tumor models, combined therapy with HRT and bispecific antibody warrants further investigation. Here, SIRPA is linked to neoplasm.